SecBot SecBot
PRESS-RELEASE ·Filed Nov 9, 2026

ZYME

Zymeworks Inc.
BULLISH
Impact 6/10
Horizonweeks Processed7d 5h ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The $250M milestone and raised guidance confirm near-term cash flow strength, but the stock's reaction will depend on the trajectory of recurring YUPELRI revenue and progress on Roche collaboration (HSR clearance). Monitor Q4 for YUPELRI growth and any updates on ex-US Ziihera milestones.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

ZYME drug pipeline →

YUPELRI

● Neutral Named in this press release
Impact
Phase
Approved
Time to market
Already approved and commercially marketed (FDA approved November 2018; China NMPA approved June 2025).
Next catalyst
None dated

What to watchYUPELRI is now a cash-flow asset within Zymeworks (ZYME), which reported Q3 2026 earnings today (Nov 9) with revenue of $256.5M, beating consensus, and raised full-year guidance to $337M-$351M. The next catalyst to watch is Zymeworks' Q4 2026 report in early 2027, which will show the first full quarter of YUPELRI contribution under Zymeworks ownership. No binary regulatory catalyst is pending for YUPELRI itself.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1
Entry
$31.46
T+0 close · Nov 9, 2026 · via day close
Latest settled
−7.60%
T+1 · $29.07
Vs SPY
−8.92%
α at T+1
Next horizon
T+5
in 10h
  1. T+0 · Nov 10 $31.46entry
  2. T+1 · 6d ago −7.60%α −8.92% · $29.07
  3. T+4 · todayOpen
  4. T+5 · in 10h Pending
  5. T+20 · in 22d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Zymeworks reported Q3 2026 revenue of $256.5M (vs consensus $221.0M) and GAAP diluted EPS of $2.28, driven by a $250M milestone from Jazz for Ziihera's FDA approval. The company raised full-year 2026 revenue guidance to $337M-$351M and adjusted EBITDA to $176M-$190M, reflecting the milestone and Theravance Biopharma acquisition.

Key Financial Metrics

EPS
$2.28
est $2.19 · +4.1%
Revenue
$256.5M
est $221.0M · +16.1% · +829.4% YoY
Rating
beat
Guidance
$337M-$351M
raised

Key Facts

  • Q3 2026 total revenue $256.5M vs $27.6M YoY, including $250M Ziihera milestone
  • GAAP diluted EPS $2.28 vs $(0.26) YoY
  • 2026 revenue guidance raised to $337M-$351M (prior $278M-$292M)
  • 2026 adjusted EBITDA guidance raised to $176M-$190M (prior $114M-$128M)
  • Closed Theravance Biopharma acquisition on Sep 23, 2026
  • Repurchased 534,381 shares for $14.0M in Q3
  • Roche collaboration for ZW209 with up to $718M in milestones plus royalties

Financial Impact

Q3 revenue $256.5M, GAAP net income $173.7M; full-year guidance raised by ~$59M at midpoint

revenueepsadjusted ebitdaguidance

Risk Factors

  • Q3 revenue includes a one-time $250M milestone; recurring revenue from YUPELRI and royalties was only ~$3.8M
  • Theravance integration costs and severance weighed on SG&A ($42.7M vs $14.1M YoY)
  • Roche collaboration subject to HSR clearance; delay could impact ZW209 timeline
  • Cash and equivalents $100.5M vs $228.8M at Dec 2025, partly due to buybacks and acquisition

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3398944

Track record

25 reports on ZYME

Performance horizon

6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
  2. Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
  4. Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
  5. Nov 9, 20267d ago Press Release Bullish 6/10 Viewing Entry $31.46 Now $26.24 −16.59% settles Dec 9
  6. Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
  7. Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  8. Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
  9. Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
  10. Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 9, 2026